hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06363890, orgStudyIdInfo id: TD02, briefTitle: Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia, acronym: AusTD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Lumen Bioscience, Inc., class: INDUSTRY, descriptionModule briefSummary: The study proposed here will determine the frequency and etiology of diarrhea in Australian adult tourists traveling to Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, Timor-Leste, and Vietnam. The results from this study will inform the feasibility and design of subsequent clinical trials of travelers' diarrhea interventions in this population., conditionsModule conditions: Travelers Diarrhea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: TAQMan Array Card, outcomesModule primaryOutcomes measure: Characterize the frequency and etiology of travelers' diarrhea in this participant population of Australian adult tourists traveling to Southeast Asia., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06363877, orgStudyIdInfo id: 5220078, briefTitle: Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Loma Linda University, class: OTHER, descriptionModule briefSummary: This is a multicenter randomized controlled trial of 1100 patients to evaluate the superiority of combined intraoperative wound irrigation with intraoperative peritoneal lavage with dilute aqueous povidone-iodine compared to normal saline in male and female patients between the ages of 18 and 80 years old undergoing emergency laparotomies with Centers for Disease Control (CDC) class 2 and 3 wounds., conditionsModule conditions: Surgical Site Infection, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 1100, type: ESTIMATED, armsInterventionsModule interventions name: Povidone-Iodine, interventions name: Normal Saline, outcomesModule primaryOutcomes measure: Surgical Site Infection, secondaryOutcomes measure: Readmission, secondaryOutcomes measure: Return to the Operating Room, secondaryOutcomes measure: Ileus, secondaryOutcomes measure: Small Bowel Obstruction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Loma Linda University Health, city: Loma Linda, state: California, zip: 92354, country: United States, contacts name: Martin G Rosenthal, MD, role: CONTACT, email: mrosenthal@llu.edu, contacts name: Martin Rosenthal, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mohamed H El-Farra, MD, role: SUB_INVESTIGATOR, geoPoint lat: 34.04835, lon: -117.26115, hasResults: False
protocolSection identificationModule nctId: NCT06363864, orgStudyIdInfo id: LL-IRB-2401, briefTitle: Investigation of Metabolomics Differences Between Metabolic Syndrome and Healthy Individuals in Taiwan, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-14, primaryCompletionDateStruct date: 2029-10-31, completionDateStruct date: 2029-10-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Leeuwenhoek Laboratories Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: The prevalence of metabolic syndrome in Taiwan has been increasing yearly. In this project, the database of blood test results from healthy and metabolic syndromes individuals will be analyzed to identify the small molecules related to the severity of metabolic syndrome. These identified small molecules could be used as biomarkers to predict the development of metabolic syndromes in the future., conditionsModule conditions: Metabolic Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Concentration changes of small molecules in blood., eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06363851, orgStudyIdInfo id: Kylo-11-I-C01, briefTitle: Single-ascending Dose Study of Kylo-11 in Healthy Subjects, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Kylonova (Xiamen) Biopharma co., LTD., class: INDUSTRY, descriptionModule briefSummary: This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-11 will be evaluated in approximately 60 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects., conditionsModule conditions: Cardiovascular Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Kylo-11, interventions name: Placebo, outcomesModule primaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax), secondaryOutcomes measure: PK parameter of time of maximum observed concentration (Tmax), secondaryOutcomes measure: PK parameter of area under the concentration time curve (AUC), secondaryOutcomes measure: Change in serum Lp(a) over time, secondaryOutcomes measure: Percent change in serum Lp(a) over time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Chengdu Xinhua Hospital, city: Chengdu, state: Sichuan, zip: 610000, country: China, contacts name: Xiaolan Yong, role: CONTACT, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06363838, orgStudyIdInfo id: ordu eah, briefTitle: Evaluation of Neuromuscular Morphometry of the Vaginal Wall, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-12-01, primaryCompletionDateStruct date: 2020-06-25, completionDateStruct date: 2020-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Gaziosmanpasa Research and Education Hospital, class: OTHER_GOV, collaborators name: T.C. ORDU ÜNİVERSİTESİ, descriptionModule briefSummary: In this prospective study, women aged between 40 and 75 years who had not undergone any vaginal surgery and had not undergone any abdominal prolapse surgery were included. Thirty-one women diagnosed with rectocele on examination were included in the study group. Thirty-one patients who underwent vaginal intervention and hysterectomy for reasons other than rectocele (colposcopy, conization, etc.) without anterior or posterior wall prolapse were included in the control group., conditionsModule conditions: Pelvic Organ Prolapse, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 62, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: epithelial thickness, primaryOutcomes measure: smooth muscle density, eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hakan Timur, city: Ordu, country: Turkey, geoPoint lat: 40.97782, lon: 37.89047, hasResults: False
protocolSection identificationModule nctId: NCT06363825, orgStudyIdInfo id: MRCTA,ECFAH Of FMU[2024]373, briefTitle: A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-12, primaryCompletionDateStruct date: 2026-04-11, completionDateStruct date: 2027-05-11, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load, conditionsModule conditions: Advanced Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 57, type: ESTIMATED, armsInterventionsModule interventions name: camrelizumab, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Tumor progression time (TTP), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: AE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xinhua Chen, status: RECRUITING, city: Fuzhou, country: China, contacts name: Yiping Chen, role: CONTACT, phone: 13805066904, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06363812, orgStudyIdInfo id: The POST, briefTitle: Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2018-03-08, primaryCompletionDateStruct date: 2021-05-15, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Fondazione Sandro Pitigliani, class: OTHER, collaborators name: Genomic Health®, Inc., collaborators name: Istituto Toscano Tumori, descriptionModule briefSummary: In some cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer the benefit of adding adjuvant chemotherapy to hormonal treatment, estimated on the basis of the classical clinico-pathological parameters, is unclear. In these cases the application of a genomic test could be useful in guiding the therapeutic choice., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 258, type: ACTUAL, outcomesModule primaryOutcomes measure: the proportion of tumor samples with a useful OncotypeDx, secondaryOutcomes measure: the proportion of patients in which the result of the test has induced a modification in the initial treatment plan, secondaryOutcomes measure: the proportion of tumor samples with an intermediate risk or not evaluable at OncotypeDx, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital of Prato, city: Prato, zip: 59100, country: Italy, geoPoint lat: 43.8805, lon: 11.09699, hasResults: False
protocolSection identificationModule nctId: NCT06363799, orgStudyIdInfo id: OST1_010, briefTitle: Osteopathic Protocol for Insomnia in College Students, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Escola Superior de Tecnologia da Saúde do Porto, class: OTHER, descriptionModule briefSummary: In this randomized controlled experimental trial, it is aimed to determine the effectiveness of an osteopathic protocol treatment for insomnia in college students. In this study, will be used the Compression of 4th ventricle (CV4) and the diaphragmatic breathing technique., conditionsModule conditions: Insomnia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: 4th ventricle compression technique and diaphragmatic breathing, interventions name: Sham Technique, outcomesModule primaryOutcomes measure: Change from the baseline insomnia episodes and symptoms through Pittsburgh questionnaire score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 28 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06363747, orgStudyIdInfo id: 123456, briefTitle: The Medically Reproducing Bariatric Surgery (MRB) II Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-03, primaryCompletionDateStruct date: 2025-06-03, completionDateStruct date: 2025-06-03, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Durham VA Medical Center, class: FED, collaborators name: Société des Produits Nestlé (SPN), descriptionModule briefSummary: Roux-en-Y (RYGB) gastric bypass reduces the size and capacity of the stomach and bypasses a portion of the small intestine which leads to decreased food intake and higher levels of a gut hormone called GLP-1 (glucagon-like-peptide-1). These changes lead to weight loss, improved blood sugars and often remission of type 2 diabetes but most patients do not qualify or want surgery. The investigators are searching for ways to make the beneficial effects of RYGB available to most type 2 diabetes patients rather than a select few that undergo RYGB.The investigators believe that parts of RYGB can be medically reproduced through a combination of diet and medicine. Once weekly injectable GLP-1 medicine that leads to weight loss and improved blood sugar control in type 2 diabetes are now FDA approved. Optifast is a medically supervised diet that safely reduces calorie intake to 800 calories per day for three months by replacing normal meals with specially prepared bars and shakes which leads to weight loss and improved blood sugar control in type 2 diabetes. Normal meals are then gradually reintroduced over 6 weeks and the bars/shakes are stopped. The investigators hypothesize that Optifast (diet) + once weekly GLP-1 will lead to weight loss and improvement in blood sugar control in type 2 diabetes similar to what is seen after RYGB., conditionsModule conditions: Type 2 Diabetes, conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Control--\[GLP-1 agonist +/- DM2 meds + medical management + nutritional/behavioral counseling\] Experimental---\[Optifast + GLP-1 agonist + medical management + nutritional/behavioral counseling\], primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Very Low Calorie Diet, outcomesModule primaryOutcomes measure: Glycemic Control, secondaryOutcomes measure: Weight lost, secondaryOutcomes measure: Medication Intensity, secondaryOutcomes measure: Health Related Quality of Life, otherOutcomes measure: Symptom Item Checklist, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Greenville VA Health Care Center, city: Greenville, state: North Carolina, zip: 27834, country: United States, geoPoint lat: 35.61266, lon: -77.36635, hasResults: False
protocolSection identificationModule nctId: NCT06363734, orgStudyIdInfo id: DAL20240409, briefTitle: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2025-12-15, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: This study is a prospective, single-arm, phase II trial. It is aimed to evaluate the efficacy and safety of the combination of osimertinib and dalpiciclib in patients with EGFR-mutant, CDK4/6 pathway aberrant, advanced NSCLC following acquired resistance to third-generation EGFR TKI., conditionsModule conditions: Non-small Cell Lung Cancer, conditions: EGFR Activating Mutation, conditions: Cell Cycle Deregulation, conditions: EGFR-TKI Resistant Mutation, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Osimertinib plus Dalpiciclib, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: disease control rate (DCR), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Progression Free Survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Thoracic Medical Oncology, Tianjin Medical University Cancer Hospital, status: RECRUITING, city: Tianjin, state: Tianjin, zip: 300060, country: China, contacts name: Peng Chen, M.D., role: CONTACT, phone: +86-22-23340123, phoneExt: 3201, email: chenpeng@tjmuch.com, contacts name: Peng Chen, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06363721, orgStudyIdInfo id: DFH00125, briefTitle: A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental Health, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Designs for Health, class: INDUSTRY, descriptionModule briefSummary: The primary purpose of this study is to evaluate the impact of a commercially-available oil rinse product (PerioPull™) on parameters of dental health among a sample of adults. PerioPull™ is commercially available and sold primarily from clinicians' offices.A 12-week pilot study will be conducted to achieve the purpose of this study. The research team hypothesizes that PerioPull™ will improve a variety of validated markers of dental health that are commonly used in clinical practice., conditionsModule conditions: Oral Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The proposed study is a 12-week pilot study of PerioPull™. Eligible participants will be recruited from within the clinical practice of the periodontist. All study outcomes will be measurements and testing during three dental visits spaced 6 weeks apart. These are typical assessments in routine clinical practice. All study outcomes are described in detail in an ensuing section., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: PerioPull™, outcomesModule primaryOutcomes measure: Plaque Index, primaryOutcomes measure: Gingival Index, primaryOutcomes measure: Pocket Depth, secondaryOutcomes measure: Intraoral Photos, secondaryOutcomes measure: MyPerioPath®, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Julian Center for Comprehensive Dentistry, status: RECRUITING, city: Ellicott City, state: Maryland, zip: 21042, country: United States, contacts name: Eugene Sambataro, DDS, role: CONTACT, phone: 410-834-0796, email: drsam@julianctr.com, contacts name: Eugene Sambataro, DDS, role: PRINCIPAL_INVESTIGATOR, contacts name: Chris D'Adamo, PhD, role: SUB_INVESTIGATOR, contacts name: Michael Jurgelewicz, DC, role: SUB_INVESTIGATOR, contacts name: David Brady, ND, DC, role: SUB_INVESTIGATOR, geoPoint lat: 39.26733, lon: -76.79831, hasResults: False
protocolSection identificationModule nctId: NCT06363708, orgStudyIdInfo id: 2024050, briefTitle: Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Zhongnan Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer., conditionsModule conditions: Endometrial Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab, interventions name: Paclitaxel, interventions name: Carboplatin, outcomesModule primaryOutcomes measure: R0 resection rate (R0 %), secondaryOutcomes measure: Pathological complete response rate (pCR%）, secondaryOutcomes measure: Objective Response Rate (ORR%), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Recurrence free survival (RFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Incidence and severity of adverse events as assessed by the NCI-CTCAE v5.0, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Central Hospital of Wuhan, city: Wuhan, state: Hubei, zip: 430014, country: China, contacts name: Xun Tian, MD,PhD, role: CONTACT, phone: 15327205656, email: tianxun@126.com, geoPoint lat: 30.58333, lon: 114.26667, locations facility: Zhongnan Hospital of Wuhan University, city: Wuhan, state: Hubei, zip: 430062, country: China, contacts name: Zheng Hu, MD,PhD, role: CONTACT, phone: 13632120686, email: Huzheng1988@163.com, geoPoint lat: 30.58333, lon: 114.26667, locations facility: Hubei maternal and child health care hospital, city: Wuhan, state: Hubei, zip: 430070, country: China, contacts name: QuanFu Ma, MD,PhD, role: CONTACT, phone: 13728133014, email: dm626925@126.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False